Composition for reducing blood sugar and application thereof

Abstract

The invention discloses a composition for reducing blood sugar, the composition comprises mushroom polysaccharide and pyrroloquinoline quinone, and the weight ratio of the pyrroloquinoline quinone to the mushroom polysaccharide is (1.5-7.5): 1000; the invention also discloses application of the composition in preparation of a hypoglycemic preparation for persistently reducing blood sugar in type 2 diabetes mellitus and early-stage diabetes mellitus. After the composition disclosed by the invention is continuously taken for a period of time, even if the composition is stopped being taken, the blood sugar can still be kept stable for at least 60 days, so that the composition has the effect of permanently reducing the blood sugar.

Description

Technical Field

[0001] The present invention relates to the technical field of lowering blood sugar, and in particular to a composition capable of permanently lowering blood sugar and an application thereof. Background Art

[0002] Currently, diabetes drugs are mainly used to control blood sugar levels to help prevent complications. According to different mechanisms of action and treatment goals, diabetes drugs can be divided into several categories, including insulin: direct insulin supplementation; sulfonylureas: lowering blood sugar by stimulating the pancreas to secrete more insulin; biguanides: reducing the amount of glucose produced by the liver and increasing the body's sensitivity to insulin; thiazolidinediones: increasing the sensitivity of body tissues to insulin and reducing the glucose released by the liver; α-glucosidase inhibitors: slowing down the absorption of carbohydrates in the small intestine, thereby lowering postprandial blood sugar levels; DPP-4 inhibitors: increasing the level of incretin hormone GLP-1 by blocking the action of the DPP-4 enzyme, thereby promoting insulin secretion and reducing glucagon secretion; GLP-1 receptor agonists and glucagon-like peptide-1 analogs: mimicking the action of the incretin hormone GLP-1 naturally produced in the human body, increasing insulin secretion and reducing glucagon secretion; SGLT2 inhibitors: preventing the kidneys from reabsorbing glucose, thereby excreting excess glucose through urine.

[0003] Although there are many kinds of drugs used to control blood sugar or treat diabetes, the mechanism of action of these drugs is to act on one or several factors that cause blood sugar to rise. As long as the drugs are stopped, these factors will recover and blood sugar will rise again, so they all need to be taken for life. So far, there is no drug that can completely cure diabetes or keep blood sugar within the normal range after stopping the drugs. Summary of the invention

[0004] In view of the above technical problems in the related art, the present invention provides a composition capable of permanently lowering blood sugar and its application, which can solve the above problems.

[0005] To achieve the above technical objectives, the technical solution of the present invention is implemented as follows: A composition for lowering blood sugar, comprising mushroom polysaccharide and pyrroloquinoline quinone, wherein the weight ratio of pyrroloquinoline quinone to mushroom polysaccharide is 1.5-7.5:1000.

[0006] Furthermore, the mushroom polysaccharide includes one or more of: Ganoderma lucidum polysaccharide, Pleurotus ostreatus polysaccharide, Pleurotus geesteranus polysaccharide, Lentinus edodes polysaccharide, Agaricus blazei murill polysaccharide, and Grifola frondosa polysaccharide.

[0007] Furthermore, 4 kg of Pleurotus ostreatus powder was taken, 5 g of pyrroloquinolone disodium salt was added, and the mixture was mixed in a small mixer to obtain the powder of the composition, wherein the content of Pleurotus ostreatus polysaccharide in the Pleurotus ostreatus powder was 30%.

[0008] Furthermore, the composition is used in the preparation of a hypoglycemic preparation for persistently lowering blood sugar in type 2 diabetes and prediabetes.

[0009] The beneficial effect of the present invention is that after taking the composition of the present application continuously for a period of time, even after stopping taking the composition, blood sugar can still be kept stable for at least 60 days, and it has the effect of permanently lowering blood sugar. DETAILED DESCRIPTION

[0010] The present invention is further described below by way of examples. It must be pointed out that these examples are used to illustrate the present invention and should not be construed as limiting the present invention.

[0011] Explanation of "Types of Diabetes": Diabetes is a chronic metabolic disease characterized by hyperglycemia (abnormally high blood sugar levels). Hyperglycemia is usually caused by insufficient insulin secretion or a poor response of the body to insulin. There are two main types of diabetes: type 1 diabetes and type 2 diabetes.

[0012] Type 1 diabetes is caused by the immune system mistakenly attacking and destroying the pancreatic beta cells that produce insulin, resulting in absolute insulin deficiency. Type 1 diabetics need lifelong insulin therapy to survive.

[0013] Type 2 diabetes is the most common form of diabetes. This type of diabetes is caused by the body's inefficient use of insulin (i.e. insulin resistance) and / or insufficient insulin production. Type 2 diabetes can be managed with lifestyle changes, oral medications and, in some cases, insulin.

[0014] About "Prediabetes": Prediabetes is the transitional stage before the onset of diabetes. It is an intermediate hyperglycemia state between normal blood sugar and diabetes. It is the key population for diabetes prevention and control. Generally, fasting blood sugar of 6.1mmol / L to 6.9mmol / L or blood sugar two hours after a meal of 7.8mmol / L to 11.0mmol / L or glycosylated hemoglobin of 5.7% to 6.4% is defined as prediabetes.

[0015] The role of some raw materials related to the present invention in treating diabetes or controlling blood sugar: (1) Polysaccharides. There are currently a large number of animal experimental reports on the role of polysaccharides in alleviating diabetes and its complications. For example, astragalus polysaccharides alleviate renal inflammation in diabetic nephropathy by inhibiting the TLR4 / NF-κB pathway or promote autophagy by targeting the lncRNA Gm41268 / PRLR pathway, thereby alleviating diabetic nephropathy; Polyporus polysaccharides alleviate diabetic symptoms by regulating the intestinal microbiota and intestinal barrier to inhibit the TLR4 / NF-kappaB pathway; Dendrobium officinale polysaccharides reduce podocyte damage in diabetic nephropathy by regulating IRS-1 / AKT signaling and promoting mitosis; Hawthorn polysaccharides alleviate symptoms of type 2 diabetes by regulating intestinal flora and short-chain fatty acids; Zhenshu Tiaozhi capsule polysaccharides improve renal damage in diabetic mice by regulating the gut-kidney axis; White lentil polysaccharides improve renal damage in diabetic mice by regulating the gut-brain axis. Improve diabetes in rats with type 2 diabetes; Ganoderma lucidum polysaccharide hydrogel accelerates diabetic wound healing by regulating macrophage polarization; Pleurotus ostreatus polysaccharide has anti-diabetic effects on streptozotocin-induced diabetic rats; Lentinan can help protect pancreatic β cells, promote insulin secretion, and lower blood sugar levels; Grifola frondosa polysaccharide or other active substances in Grifola frondosa such as α-glucan can improve diabetes by improving the immune response in the pathogenesis of diabetes to reduce the degree of damage to pancreatic β cells, or improve insulin resistance by regulating the composition of intestinal microorganisms in diabetic rats.

[0016] However, the above experimental results are mainly animal experiments, and their effects are all focused on alleviating the symptoms or complications of diabetes, and have not achieved continuous control of blood sugar within a normal range.

[0017] (2) PQQ (pyrroloquinoline quinone) has been reported to have a hypoglycemic effect, and its mechanism is as follows: Insulin resistance plays a key role in the development of type 2 diabetes, and alleviating insulin resistance is considered to be the main clinical strategy for improving type 2 diabetes. Many evidences indicate that PTP1B plays a key role in insulin resistance. PTP1B negatively transduces insulin signals by catalyzing the dephosphorylation of tyrosine residues in IRand IR substrate-1. PQQ induces ligand-independent insulin signal activation by inhibiting cellular PTP1B and enhances glucose uptake in mice through translocation of glucose transporter 4.

[0018] According to the above mechanism of action, if PQQ is stopped, the inhibition of ligand-independent insulin signal activation induced by cellular PTP1B will be terminated, and the hypoglycemic effect will be eliminated. Therefore, the use of PQQ alone cannot achieve the purpose of continuously controlling blood sugar within the normal range.

[0019] In summary, both the existing drugs and the aforementioned raw materials related to the present invention have the problem of "dependence" in lowering blood sugar, that is, although these drugs and raw materials have the effect of lowering blood sugar, if they are stopped, blood sugar will rise to the original state (the so-called "rebound"), and there is no change in the patient's ability to control blood sugar when they are separated from the drugs or the above-mentioned raw materials.

[0020] In view of the above problems, the present application provides a composition for lowering blood sugar, which comprises mushroom polysaccharide and pyrroloquinoline quinone (or pyrroloquinoline quinone salt), wherein the weight ratio of pyrroloquinoline quinone to mushroom polysaccharide is 1.5-7.5:1000. The composition is used in type 2 diabetes and prediabetes to permanently lower blood sugar.

[0021] In order to demonstrate its effect, this application is verified through specific case experiments.

[0022] All the raw materials used in the present invention belong to "food" or "medicinal and edible substances" in the food catalog, and the daily consumption is strictly controlled within the consumption range in the national food catalog. Therefore, there is no safety problem when giving it to patients.

[0023] In the specific implementation process, the present invention uses 27 patients diagnosed with prediabetes as experimental subjects. The reason why patients with prediabetes are used as experimental subjects is due to the following three considerations: (1) Both patients with prediabetes and patients with diabetes have blood sugar levels higher than normal, but the degree of the higher than normal value is different. There is no essential difference in pathology. Therefore, the experimental results obtained by using patients with prediabetes as experimental subjects are also applicable to the experimental results of patients with diabetes as experimental subjects. (2) According to the current diabetes treatment plan, most diabetic patients need drug control, which will interfere with the use of the composition of the present invention and is not conducive to the inspection of the effect of the present invention; while patients with prediabetes do not need to use drugs, but only need to control their diet, so there will be no interference with the results of the experiment. (3) From the perspective of the safety of the subjects, the blood sugar concentration of diabetic patients is higher, and the probability of complications during the experiment is relatively high, so there will be certain risks in the experiment; while patients with prediabetes basically have no risk of complications in the short term (the longest experiment time is no more than 3 months).

[0024] The present invention tested 27 patients diagnosed with prediabetes, 11 males and 16 females, aged 35-56 years old, with fasting blood sugar levels of 6.1-6.9 mmol / L. All patients followed the doctor's advice, did not use any medication, and only controlled blood sugar levels through diet. The subjects participated voluntarily, and there was no significant difference in the general data between the experimental group and the control group (P>0.05, see Table 1).

[0025] In the present invention, blood sugar is measured by a home blood glucose meter (brand model: Yuyue 582; manufacturer: Jiangsu Yuyue Medical Equipment Co., Ltd.). The sample is taken twice a day, brewed with 50-100 ml of warm water (temperature not exceeding 60 degrees Celsius) within 2 hours after breakfast and dinner respectively.

[0026] Embodiment 1: Preparation of the composition of the present invention: Take 4 kg of Pleurotus ostreatus powder (the content of Pleurotus ostreatus polysaccharide is 30%, provided by Hubei Yongse Biotechnology Co., Ltd.), add 5 g of PQQ (disodium pyrroloquinolone, provided by Hubei Meiqi Health Technology Co., Ltd.), mix well in a small mixer, and package 2 g / bag (for polysaccharide + PQQ group).

[0027] The control test used 2 kg of raw material of Pleurotus ostreatus powder, which was directly packaged into 2 g / bag (for the single polysaccharide group).

[0028] The above samples are tested according to GB / T 29602 standard and can enter the test only after they meet the quality standards.

[0029] Embodiment 2: Clinical trials: The subjects were divided into three groups: control group, single polysaccharide group, and polysaccharide + PQQ group. The control group followed the doctor's advice and only controlled blood sugar levels through diet; the single polysaccharide group took oyster mushroom powder twice a day, one bag each time (i.e. 2g) in addition to controlling blood sugar levels through diet; the polysaccharide + PQQ group took oyster mushroom powder + PQQ combination twice a day, one bag each time (i.e. 2g) in addition to controlling blood sugar levels through diet. All subjects had their fasting blood sugar measured before breakfast every day. The subjects in the single polysaccharide group and the polysaccharide + PQQ group stopped taking the medicine after taking it for 30 consecutive days, and continued to measure their fasting blood sugar every day for 60 consecutive days. The test results are shown in Table 1, where: for the single polysaccharide group and the polysaccharide + PQQ group, the fasting blood sugar on the 60th day of the test refers to the data measured 30 days after stopping taking it, and the fasting blood sugar on the 90th day of the test refers to the data measured 60 days after stopping taking it. The data are presented in the form of "mean ± standard deviation", and the P value is expressed in excel (Microsoft ® Excel for Mac, version: 15.23.2) comes with T.TEST function calculation.

[0030] Table 1 Fasting blood glucose values ​​of subjects *1, compared with the control group, P>0.05; *2, compared with the control group, P>0.05; compared with the single polysaccharide group, P>0.05; *3, compared with the control group, P < 0.05; *4, compared with the control group, P<0.05; compared with the single polysaccharide group, P>0.05; *5, compared with the control group, P < 0.05; *6, compared with the control group, P<0.05; compared with the single polysaccharide group, P<0.05; *7, compared with the control group, P>0.05; *8, compared with the control group, P<0.01; compared with the single polysaccharide group, P<0.01; *9, compared with the control group, P < 0.01; *10, compared with the control group, P<0.05; compared with the single polysaccharide group, P<0.01.

[0031] The experimental results of the control group showed that for subjects with prediabetes, dietary control can stabilize blood sugar, but cannot lower blood sugar (P>0.05 of blood sugar concentration during the experiment, no significant difference).

[0032] The test results of the single polysaccharide group showed that for subjects with prediabetes, oral administration of a single polysaccharide can effectively lower fasting blood sugar (after taking it for 30 days, i.e., the 30th day of the test, compared with the control group, P < 0.05, with a significant difference); but after stopping taking it, fasting blood sugar will rebound (after stopping for 30 and 60 days, i.e., the 60th and 90th days of the test, compared with the control group, P > 0.05, with no significant difference).

[0033] The test results of the polysaccharide + PQQ group showed that for subjects with prediabetes, oral polysaccharide + PQQ can effectively reduce fasting blood sugar (after taking it for 30 days, that is, the 30th day of the test, compared with the control group, P < 0.01, with a particularly significant difference), and the reduction is greater than that of oral single polysaccharide (after taking it for 30 days, that is, the 30th day of the test, compared with the single polysaccharide group, P < 0.05, with a significant difference). And after stopping taking it, this blood sugar-lowering effect can be maintained for at least 60 days (after stopping taking it for 30 days, that is, the 60th day of the test, compared with the 30th day of the test, P > 0.05, no significant difference; after stopping taking it for 60 days, that is, the 90th day of the test, compared with the 30th and 60th days of the test, P > 0.05, no significant difference).

[0034] The above results show that the combination of polysaccharides + PQQ has a synergistic effect in lowering blood sugar. The blood sugar of the subjects has been effectively lowered, and the blood sugar has been kept within the normal range within 60 days after stopping taking the sample (there will be no "rebound" phenomenon for a long time, which solves the problem of "dependence" to a certain extent), achieving a fundamental solution to the problem of high blood sugar.

[0035] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A composition for lowering blood sugar, characterized in that: The composition comprises mushroom polysaccharide and pyrroloquinoline quinone, wherein the weight ratio of pyrroloquinoline quinone to mushroom polysaccharide is 1.5-7.5:1000.

2. A composition for lowering blood sugar according to claim 1, characterized in that: The mushroom polysaccharide includes one or more of ganoderma lucidum polysaccharide, pleurotus ostreatus polysaccharide, pleurotus geesteranus polysaccharide, lentinus edodes polysaccharide, Agaricus blazei murill polysaccharide and maitake mushroom polysaccharide.

3. A composition for lowering blood sugar according to claim 2, characterized in that: 4 kg of Pleurotus ostreatus powder was taken, 5 g of pyrroloquinolone disodium salt was added, and the mixture was mixed in a small mixer to obtain the powder of the composition. The content of Pleurotus ostreatus polysaccharide in the Pleurotus ostreatus powder was 30%.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of a hypoglycemic preparation for sustained blood sugar reduction in type 2 diabetes and prediabetes.

Images